Alvotech is a global biopharmaceutical company, focused on developing biosimilar versions of leading monoclonal antibodies molecules.
Alvotech has raised €144M across 2 funding rounds from 2 investors, most recently a Debt round in Jan 2026. Based in Reykjavík, Iceland; founded 2013; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2026-01-02 | Debt | €100M | GoldenTree Asset Management | View deal → |
| 2019-01-01 | Other | €44M | Fuji Pharma | View deal → |
